Media Inquiries

If you are interested in interviewing a CCR scientist, OR you are a scientist who has been contacted by a member of the media, please contact the NCI Press Office at ncipressofficers@mail.nih.gov or by phone at 240.760.6600.

News and Events

Celebrating CCR Careers: Zhengping Zhuang, M.D., Ph.D.

Zhengping Zhuang, M.D., Ph.D., is a world-renowned expert in experimental pathology, cancer genetics and cancer therapeutics. He has contributed to biotechnological advancements, drug development and clinical translation of his work in tumor biology. After 32 years serving the NCI, he has announced his retirement.

The middle portion of the gastrointestinal tract is a common location for cancerous neuroendocrine tumors to form.

Clinical trial evaluates drug combination for inoperable neuroendocrine tumors

Neuroendocrine tumors occur in cells of the endocrine and nervous systems. A combined phase I/II clinical trial at the NIH Clinical Center evaluates the effectiveness of a combination of two agents that may work in complementary ways to target inoperable or metastatic neuroendocrine tumors.

image of female physician using a stethoscope on a young female patient

Clinical trial researching T-cell therapy for sarcoma

John W. Glod, M.D., Ph.D., Associate Research Physician in the Pediatric Oncology Branch, is leading NCI’s participation in a clinical trial researching T-cell therapy for sarcomas.

Three-dimensional illustration of a T cell attacking a cancer cell.

T-cell imbalance can impact immunotherapy outcomes

The rapid growth of a patient’s cancer following immune checkpoint inhibitor therapy, known as hyperprogressive disease, is an unexpected treatment outcome that is challenging to predict or study. New results show that a T-cell imbalance in the tumor microenvironment can trigger the condition.

A spheroid of breast cancer cells grown in a three-dimensional matrix.

Mapping cells’ mechanical properties for insight into metastasis

A new approach allows researchers to investigate cells’ mechanical properties in tissue-like environments.

Clinical trial researching therapy for tumors that have spread to the lining of the abdomen

A clinical trial led by Andrew M. Blakely, M.D., Assistant Research Physician in the Surgical Oncology Program, is researching a combination drug therapy for peritoneal carcinomatosis, a condition in which tumors have spread along the lining of the abdomen from the appendix, colon, ovary or mesothelioma.

Clinical trial researches drug therapy for bone marrow neoplasms

A clinical trial led by Steven Z. Pavletic, M.D., Senior Clinician in the Immune Deficiency Cellular Therapy Program, is researching a therapy for myelodysplastic syndromes (MDS), a group of bone marrow neoplasms.

Scan of bone marrow from mice with non-alcoholic fatty liver disease

Liver cancer may unexpectedly be influenced by platelets

Platelets have long been associated with more aggressive cancers; however, new results show that these cell fragments release molecules with anti-tumor properties against liver cancer, reducing tumor burden in mice. The results provide detailed insights into the mysterious role of platelets in cancer progression.

Clinical trial researching therapy for prostate cancer

A clinical trial led by Ravi A. Madan, M.D., Senior Clinician in the Genitourinary Malignancies Branch, is researching a combination drug therapy for prostate cancer.

Stock image of female African-American doctor with female patient in office setting.

Clinical trial researching therapy for cancers of the reproductive system

A clinical trial led by Jung-Min Lee, M.D., Lasker Clinical Research Scholar in the Women’s Malignancies Branch, is researching a combination drug therapy for cancers of the ovaries, fallopian tubes or peritoneum.

TOP3B (pink structure) and DDX5 (green structure) are working together to unwind and cut a tangled R-loop.

Study finds that enzyme can disentangle strands of DNA and RNA

R-loops are three-stranded hybrid structures of DNA and RNA that play important regulatory functions in cells. Tangled R-loops can cause a number of issues in the genome and subsequently affect people’s health. CCR researchers have uncovered the mechanisms that the enzyme topoisomerase 3B uses to disentangle problematic R-loops.

Breadcrumb

News and Events